ALC vs GKOS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ALC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALC and GKOS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALC and GKOS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alcon makes the things an ophthalmologist and an optometrist use every day. The Surgical division sells cataract equipment (the Unity VCS and CS platforms, LenSx femtosecond lasers, the ARGOS biometer, NGENUITY 3D visualization, the Constellation vitreoretinal system) plus the intraocular lenses that get implanted during those procedures, including the PanOptix and Vivity presbyopia-correcting families and the newer Clareon TruPlus monofocal and toric lenses. The Vision Care division sells contact lenses (Precision1, Precision7, Dailies Total1, Total30) and ocular health products (Systane dry eye drops, allergy and lens care lines, and the recently launched Tryptyr dry eye drug). In the first quarter of 2026 the split was roughly $1.5 billion Surgical and $1.2 billion Vision Care on $2.7 billion of total sales, so Surgical is the larger side but not overwhelmingly so. The company is headquartered in Geneva, employs about 26,000 people, traces its roots to a 1945 Fort Worth pharmacy, and has been independent since Novartis spun it off in April 2019. It passed 175 million cumulative IOL implants in March 2026.

Full ALC guide

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. The company sells through eye surgeons and clinics in the US and internationally, and reported record Q1 2026 net sales of roughly $150.6 million, up about 41% year over year, with its US glaucoma franchise up roughly 58% and iDose TR contributing around $54 million.

Full GKOS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALC drivers: Demographics that do not switch off; An unusually dense 2026 product cycle.
• GKOS drivers: iDose TR ramp; Corneal health and Epioxa.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case a 5% to 7% constant currency growth guide gets revised down again after multiple cuts already in 2025 and 2026. For GKOS, glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALC if you believe its drivers more; GKOS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALC and GKOS guides.

ALC. The two P/E figures tell the whole disagreement. Trailing GAAP earnings are depressed by amortization from the Novartis separation and by the cost of running several product launches at once, which is why the stock screens at roughly 41 times trailing and roughly 18 times forward. Gross margin sits near 55% and free cash flow conversion is steady, so the question is not whether the business generates cash, it is whether the 2026 margin expansion guide of 70 to 170 basis points holds when Q2 results arrive on August 10, 2026. Shares trade near the bottom of a $61.84 to $90.41 52-week range against an average analyst target around $87.

GKOS. Glaukos combines roughly 40% revenue growth with ongoing net losses, so it screens as a high-multiple growth medtech rather than a value name (negative trailing P/E). The debt-free balance sheet and roughly $280 million in cash fund the iDose TR and Epioxa launches. Wall Street price targets in 2026 ranged widely, from about $72 to $165, reflecting disagreement over how quickly the newer products scale.

Headline figures (approximate, August 2026): ALC shows revenue (ttm) ~$10.6 billion, up ~7%, q1 2026 sales ~$2.7 billion, up ~10% reported and ~6% in constant currency, segment split (q1 2026) ~$1.5 billion Surgical, ~$1.2 billion Vision Care, earnings per share ~$1.66 trailing GAAP; core diluted EPS was ~$0.85 in Q1 2026, up ~16%; GKOS shows revenue (ttm) ~$470M, q1 2026 net sales ~$150.6M (up ~41% YoY), 2026 revenue guidance ~$620M to $635M, q1 2026 net loss ~$19.8M (~$0.34/share).

ALC and GKOS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALC and GKOS exposure against your real portfolio. It is not an investment adviser.